Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi

Three years after launching with three preclinical assets from AstraZeneca’s R&D center in Shanghai and $132.5 million in cash, Dizal Pharma has drawn marquee new investors in for a $100 million reload.